YC-1 attenuates hypoxia-induced pulmonary arterial hypertension in mice
Authors:
- Sun-Yong KimSKSun-Yong Kim
- Ji Hyun LeeJLJi Hyun Lee
- Yun-Song LeeYLYun-Song Lee
- 1 December 2011
- journal article
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 24 (6) , 638-646
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Compelling Evidence of Long-Term Outcomes in Pulmonary Arterial Hypertension?JACC, 2011
- HIF and the Lung: Role of Hypoxia-inducible Factors in Pulmonary Development and DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Update in Pulmonary Arterial Hypertension 2007American Journal of Respiratory and Critical Care Medicine, 2008
- Pulmonary arterial hypertension: current therapeutic strategiesNature Clinical Practice Cardiovascular Medicine, 2007
- Pathobiology of Pulmonary HypertensionAnnual Review of Pathology: Mechanisms of Disease, 2007
- Hypoxia-Inducible Factor-1 (HIF-1)Molecular Pharmacology, 2006
- Pulmonary Arterial HypertensionCirculation, 2006
- Pharmacology and potential therapeutic applications of nitric oxide‐releasing non‐steroidal anti‐inflammatory and related nitric oxide‐donating drugsBritish Journal of Pharmacology, 2002
- Expression of angiogenesis‐related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesisThe Journal of Pathology, 2001
- Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1αJournal of Clinical Investigation, 1999